Protai Advances AI-Driven Drug Discovery with Novel TNFα Targeting and Protein Degradation Technologies
核心洞察
Protai (搜索) presented breakthrough findings on TNFα (搜索) transient pocket modeling at major scientific conferences, integrating AI-driven conformational modeling with mass-spectrometry-based structural proteomics to open new therapeutic avenues for inflammatory and autoimmune diseases (搜索).
The company's AIMS™ platform reveals hidden, dynamic druggable pockets in complex proteins like TNFα (搜索), enabling rational design of small-molecule therapeutics where traditional structure-based approaches fall short.
Protai (搜索) showcased an innovative KAT6A degrader (搜索) designed through its AIMS™ platform, demonstrating advances in targeted protein degradation technology.
Protai (搜索), a structural proteomics and AI-driven biotechnology company, announced significant advances in drug discovery technology through presentations at four major scientific conferences in October 2025. The company showcased breakthrough findings in TNFα (搜索) signaling complex modeling and targeted protein degradation, positioning its AIMS™ platform as a transformative approach to discovering protein-protein interaction inhibitors and induced proximity therapeutics.
TNFα Breakthrough Opens New Therapeutic Pathways
At the 13th Symposium on Structural Proteomics, Dr. Anjana Shenoy, Protai (搜索)'s Head of Proteomics, presented breakthrough findings on TNFα (搜索) transient pocket modeling. The research integrates AI-driven conformational modeling with mass-spectrometry-based structural proteomics, opening new therapeutic avenues for modulation of TNF signaling. This pathway is implicated in multiple inflammatory and autoimmune diseases (搜索), representing a significant opportunity for therapeutic intervention.
The company's approach addresses a critical challenge in drug discovery by revealing hidden, dynamic druggable pockets in complex proteins such as TNFα (搜索). As CEO Eran Seger explained at MoML@MIT 2025, the AIMS™ platform bridges AI and structural proteomics to enable rational design of small-molecule therapeutics where traditional structure-based approaches fall short.
Targeted Protein Degradation Advances
Protai (搜索)'s CTO Kirill Pevzner presented the company's latest achievements in targeted protein degradation at the TPD & Induced Proximity Summit in Boston. The presentation highlighted an innovative KAT6A degrader (搜索) designed through Protai's AIMS™ platform, demonstrating the technology's capability to develop novel therapeutic modalities beyond traditional small-molecule inhibitors.
AIMS™ Platform Technology
The AIMS™ (AI-Mass-Spectrometry) platform represents Protai (搜索)'s core technological innovation, utilizing AI-based structural modeling and experimental proteomics to model large protein complexes. This integrated approach enables the discovery of novel small molecules and degraders for modulating these complexes, combining proteomics-driven experimental evidence with next-generation AI modeling.
"Our mission is to transform how the industry discovers PPI inhibitors and induced proximity therapeutics," said Eran Seger, CEO and co-founder of Protai (搜索). "By combining proteomics-driven experimental evidence with next-generation AI modeling, we are revealing opportunities that were previously invisible to classical drug discovery methods."
Strategic Expansion into Immunology
Protai (搜索)'s participation in ACR Convergence 2025 in Chicago marks part of its strategic expansion into the Immunology & Inflammation space. The company's pipeline spans oncology (搜索) and immunology, with programs targeting large clinical indications with significant unmet medical needs.
The biotechnology company's approach integrates mass-spectrometry-based structural proteomics, AI modeling, and experimental validation to map dynamic protein conformations and identify novel drugs. This proteomics-aware-AI methodology positions Protai (搜索) to address challenging targets that have been difficult to drug using conventional approaches.